The cardiovascular effects of novel weight loss therapies
Usman MS, Davies M, Hall ME, et al.
European Heart Journal. 2023;ehad664.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Hankosky ER, Wang H, Neff LM, et al.
Diabetes Obes Metab. Pub. online 6 Nov 2023.
Leggi
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK
Greenwood SA, Young HML, Briggs J, et al.
Lancet Digit Health. 2023:S2589-7500(23)00204-2.
Leggi
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study
Lieverse TTGF, Puchades MJ, Mulder UDJ, et al.
Diabetes Obes Metab. Pub. online 5 Nov 2023.
Leggi
Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: an age‐period‐cohort analysis
Liu W, Zhang D, Wang R, et al.
Diabetes Obes Metab. Pub. online 7 Nov 2023.
Leggi
Ascertainment of minimal clinically important differences in the diabetes distress scale–17: a secondary analysis of a randomized clinical trial
Banks J, Amspoker AB, Vaughan EM, et al.
JAMA Netw Open. 2023;6(11):e2342950.
Leggi
Type 2 diabetes and colorectal cancer risk
Lawler T, Walts ZL, Steinwandel M, et al.
JAMA Netw Open. 2023;6(11):e2343333.
Leggi
A randomised controlled trial assessing the impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for people with type 1 diabetes (PACE)
Rilstone SK, Oliver N, Godsland IF, et al.
Diabetes Technol Ther. Pub. online 9 Nov 2023.
Leggi
Role of glycosuria in SGLT2 inhibitor-induced cardio-renal protection: a mechanistic analysis of the CREDENCE trial
Ferrannini E, Solini A, Baldi S, et al.
Diabetes. 2023;db230448.
Leggi
HOMA-IR and the Matsuda Index as predictors of progression to type 1 diabetes in autoantibody-positive relatives
Petrelli A, Cugnata F, Carnovale D, et al.
Diabetologia. Pub. online 2 Nov 2023.
Leggi